Swipe to navigate
This is Modal Title
Myeloma CellQuest Grant
We’re thrilled to announce the Myeloma CellQuest Grant, enabling researchers to accelerate transformative discoveries that could reshape our knowledge, diagnosis and treatment of Multiple Myeloma.
This is Modal Title
Application Note
CD138+ Plasma Cell Enrichment directly from Bone Marrow
CD138 is vital for diagnosing plasma cell tumors and Multiple Myeloma. Traditional bone marrow analysis using the ficoll method is laborious and can lose key antigens like CD138. This app note showcases the MARS® platform’s efficiency in isolating CD138+ cells from raw bone marrow, enabling quicker and dependable CD138 expression analysis.
Application Note
CD34+ Cell Isolation from Cord Blood MNC
CD34+ cells are cruicial for understanding hematopoiesis, hematological conditions, and regenerative medicine. Their isolation from Cord Blood MNC is key for hematopoietic stem cell research and treatment breakthroughs. The MARS® Platform optimizes CD34+ cell enrichment, bolstering purity and viability, aiding in the evolution of personalized cellular therapies.
Brochure
MARS® Bar Platform Brochure
This is Modal Title
This is Modal Title
Liping Yu
VP of Applications
Liping leads application development, combining reagent, software, and MARS® platform to offer integrated solutions. She earned her PhD in Biophysics from Carnegie Mellon University and underwent postdoc training at Beckton Dickinson. With over a decade in the biotech sector, she’s directed innovative projects and handled partnerships. Her core expertise lies in cell analysis, separation, and analytical instruments.
This is Modal Title
Our global team
Ajay Johni
EMEA & APAC
Ajay serves as the commercial lead for MARS users in EMEA and APAC, leveraging more than two decades of expertise in life science tools. With a proven track record of guiding solutions from the bench to the clinic, he has a robust background in commercial leadership and strategic market development. Ajay has held positions within Life Technologies and various startups focused on genomics, proteomics, and nanomedicine.
This is Modal Title
Our global team
Chris Hammerquist
USA
Chris is a dynamic, strategy-driven commercial leader with a solid footing in Clinical Diagnostics, Biotech, and Pharmaceuticals. He holds a BS in Biology from Rowan University and a certification in “Strategic Business Planning” from Wharton School of Business. A former Operations Specialist in the U.S. Navy, Chris has taken on leadership roles at Roche Diagnostics, Neta Scientific, and Miltenyi Biotech.
This is Modal Title
Our global distributors
Our Global Distributor Team stands ready to facilitate your research journey, no matter where in the world you are. Committed to providing tailored solutions, support, and dedicated expertise, ensuring your research advances without boundaries. Reach out to us – we’re here for you, bridging geographical divides and pioneering research potentials together.
This is Modal Title
MARS® MAG Premium Line of Reagents
Achieve seamless cell isolation with unmatched purity using the MARS® MAG Premium Line. Developed in partnership with STEMCELL Technologies, these reagents facilitate quick and straightforward isolation of various cells, including CD138+ Plasma cells and CD34+ Stem Cells. With protocols tailored for MARS® instruments, the kits offer a comprehensive cell isolation solution for a rapid, automated, gentle, and proficient cell isolation.
